# A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

> **NCT05268952** · NA · UNKNOWN · sponsor: **University Hospital, Antwerp** · enrollment: 100 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **OTHER:** Liquid biopsies
- **OTHER:** Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)

## Key facts

- **NCT ID:** NCT05268952
- **Lead sponsor:** University Hospital, Antwerp
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-27
- **Primary completion:** 2025-05-27
- **Final completion:** 2025-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05268952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05268952, "A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05268952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*